Houssein Youness, MD
Pulmonary Disease · Martinsburg, WVNPI 1841331105
Payments from drug & device makers
What this record shows
This record is dominated by education: $6,000 of the $9,611 with a category attached, or 62.4%. Intuitive Surgical accounts for 68.8% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2022 at $6,405 and has fallen 86.7% since, to $851 in 2025.
Across 84 payments — averaging $114.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$801
- Pulmonx Corporation$752
- AbbVie$321
- Olympus America Inc.$187
- GSK$147
- plus $794 from 15 others
Across 6 payments — averaging $3587.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dompe Farmaceutici S.p.a.$22K
What the payments were for
- Speaking & faculty fees$7508%
- Travel & lodging$8499%
- Food & beverage$2,01321%
- Education$6,00062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $6,609 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $801 |
| Pulmonx Corporation | 5 | $752 |
| AbbVie | 14 | $321 |
| Olympus America Inc. | 2 | $187 |
| GSK | 9 | $147 |
| Boehringer Ingelheim | 7 | $144 |
| Gilead | 6 | $133 |
| Sunovion Pharmaceuticals Inc. | 4 | $85 |
| Genentech USA, Inc. | 5 | $83 |
| Bayer | 3 | $52 |
| Sanofi | 2 | $51 |
| AstraZeneca | 4 | $46 |
| Merck | 3 | $46 |
| Vifor Pharma, Inc. | 2 | $34 |
| Olympus Corporation Of The Americas | 1 | $26 |
| Novartis | 1 | $23 |
| Chiesi USA, Inc. | 1 | $19 |
| Insmed, Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,611 in reported general payments places this provider in the 85th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $50,860 |
| Spiriva RespimatTiotropium Bromide | 11 | $8,763 |
| Roflumilast | 24 | $3,414 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $400 |
| Prednisone | 12 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $147 | $50,86059 claims |
| Boehringer IngelheimSpiriva Respimat | $144 | $8,76311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Martinsburg
- Phillip AguilaMartinsburg$21K
- Feroz NooriMartinsburg$3K
- Richard CatlettMartinsburg$3K
- Hafiz Muhammad ZubairMartinsburg$2K
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
- Maria BoustaniBeckley$95K
- Ramzi HaddadinBeckley$43K
- Salam RajjoubBridgeport$29K
- Peter KochupuraMorgantown$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.